Improvement Effect of Transcranial Direct Current Stimulation (tDCS) Applied During Exercise Training in Stroke Patients With Upper Limb and Hand Motor Function

September 20, 2022 updated by: Yun-Hee Kim
The purpose of this study was to improve the effect of Transcranial Direct Current Stimulation (tDCS) applied during exercise training in stroke patients with upper limb and hand motor function.

Study Overview

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients aged 19 to 80 years
  • Less than 58 FMA Upper scores
  • Patients whose lesions do not include stimulation regions
  • Patients with stroke with more than 3 months of onset

Exclusion Criteria:

  • Difficult to communicate due to severe language impairment.
  • Accompanied by an existing serious neurogenic disease
  • Existing significant psychiatric disorders such as major schizophrenia, bipolar disorder
  • If there are difficulties in conducting the research
  • Any patients who are judged by the investigator to be difficult to participate in this study
  • Patients with contraindicated MRI scans

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Hand Tasks + M1(1mA) & aIPS(1mA) tDCS
20 minutes of Hand Taks + applying 30 minutes of M1(1mA) & aIPS(1mA) tDCS and fNIRS
30 minutes of intervention including tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
Active Comparator: Hand Tasks + Sham tDCS
20 minutes of Hand Tasks + 30 minutes of sham tDCS and fNIRS
30 minutes of intervention including sham tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Fugl-Meyer Assessment
Time Frame: Session 0 (initial visit);; Session 10 (at approximatel 4 weeks)
The score is a stroke-specific, performance-based impairment index. The degree of impairment of upper and lower limbs is measured.
Session 0 (initial visit);; Session 10 (at approximatel 4 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in 9-hole pegboard test
Time Frame: Baseline(initial visit); Session 10 (at approximatel 4 weeks)
The test is a standardized, quantitative assessment used to measure finger dexterity of a patient.
Baseline(initial visit); Session 10 (at approximatel 4 weeks)
Change in Grip & Tip pinch strength
Time Frame: Baseline(initial visit); Session 10 (at approximatel 4 weeks)
The test is to measure the maximum isometric strength of hand, forearm, and finger muscles.
Baseline(initial visit); Session 10 (at approximatel 4 weeks)
Change in Sequential finger tapping reaction time and accruacy
Time Frame: Baseline(initial visit); Session 10 (at approximatel 4 weeks)
Response time and accuracy are measured during finger tapping task.
Baseline(initial visit); Session 10 (at approximatel 4 weeks)
Change in Jebsen-Taylor hand function test
Time Frame: Baseline(initial visit); Session 10 (at approximatel 4 weeks)
This test is a standardized and objective measure of fine and gross motor hand function using simulated activities of daily living (ADL).
Baseline(initial visit); Session 10 (at approximatel 4 weeks)
Change in Box and Block test
Time Frame: Baseline(initial visit); Session 10 (at approximatel 4 weeks)
The test is used to measure the gross manual dexterity of a patient, or of a person using an upper limb prosthetic device.
Baseline(initial visit); Session 10 (at approximatel 4 weeks)
Changes in motor evoked potential
Time Frame: [Time Frame: session 0 (initial visit); session 10 (at approximately 4 weeks)]
Resting motor threshold (rMT) and amplitude of motor evoked potential in first dorsal interosseous muscle are measured. These outcomes are measured by transcranial magnetic stimulation over the motor hotspot. The rMT is defined as the minimum stimulus intensity that produced a minimal motor evoked response at rest. The amplitude means peak to peak of the muscle response.
[Time Frame: session 0 (initial visit); session 10 (at approximately 4 weeks)]
Changes in Brain activation of resting-state functional MRI
Time Frame: [Time Frame: session 0 (initial visit); session 10 (at approximately 4 weeks)]
Measure of Neuroplasticity
[Time Frame: session 0 (initial visit); session 10 (at approximately 4 weeks)]

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 11, 2022

Primary Completion (Actual)

August 31, 2022

Study Completion (Actual)

August 31, 2022

Study Registration Dates

First Submitted

March 1, 2022

First Submitted That Met QC Criteria

March 9, 2022

First Posted (Actual)

March 11, 2022

Study Record Updates

Last Update Posted (Actual)

September 21, 2022

Last Update Submitted That Met QC Criteria

September 20, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe